Board meeting on Oct 28 to consider Q2 FY27 results

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹859.00

prior close

₹865.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.8%+0.6% vs market

Pharmaceuticals peers, median of 167sector-0.1%+1.6% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+1.7

15m

+2.1

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.8+0.6-0.1+1.6

Next day

+2.7+1.0+1.6-0.1+2.8

+1.1+1.7-0.7-0.3+1.4

+0.9+0.1+0.9-1.0+1.9

+2.1+0.8+1.3-0.8+2.9

-2.8-0.9-1.9-2.2-0.6

-3.4-4.5+1.1-4.7+1.3

15d

+7.2-4.8+12.0-2.7+9.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs has informed exchanges that its Board will meet on October 28, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the limited review reports of the auditors. The insider trading window remains closed from October 1 to October 30, 2026. This is a routine pre-results intimation under SEBI LODR regulations.

Likely market impact

Routine pre-results announcement. Watch for actual Q2 numbers on Oct 28. Stock may see volatility around results.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹610.5 Cr	₹418.3 Cr	+45.9%
Operating profit	₹89.68 Cr	₹39.28 Cr	+128.3%
Profit after tax	₹71.47 Cr	₹27.92 Cr	+156.0%
EBITDA margin	21.8%	17.9%	+3.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.